Reform Marijuana Laws NORML Site Map Contact Us About Marijuana Law Reform Media Contact About Marijuana Law Reform Home
Working to reform marijuana laws
search by
Click here to navigate by map
State Laws | Leyes Estatales
 
 
 
 
 
Get NORML's eZine
Legislative Alerts, News & Analysis from NORML

Details & Privacy


Get NORML's eZine
Meet Others, Share Stories
 

Home > News Archive > 2008 > Inhaled Cannabis Reduces Central And Peripheral Neuropathic Pain, Study Says

Inhaled Cannabis Reduces Central And Peripheral Neuropathic Pain, Study Says

Share This Page Share This Page on digg Share This Page on Reddit Share This Page on del.icio.us Share This Page on Stumble Upon Share This Page on Facebook Share This Page on Twitter Check our RSS Feeds

May 8, 2008 - Davis, CA, USA

Davis, CA: Cannabis significantly reduces neuropathic pain compared to placebo and is well tolerated by patients with chronic pain conditions, according to clinical trial data to be published in The Journal of Pain.

Investigators at the University of California at Davis, in conjunction with the University of California Center for Medical Cannabis Research (CMCR), assessed the efficacy of inhaled cannabis on pain intensity among 38 patients with central and/or peripheral neuropathic pain in a randomized, placebo-controlled, crossover trial. Researchers reported that smoking low-grade (3.5 percent THC) and mid-grade (7 percent THC) cannabis equally reduced patients’ perception of spontaneous pain.

"[A] significant … reduction in [a 100-point visual analog scale of] pain intensity per minute was noted from both 3.5 percent and 7 percent cannabis compared to placebo," authors wrote. "Separate appraisals using the patient global score and multidimensional [eleven-point neuropathic pain scale also] revealed that both active agents alleviated pain compared with placebo."

Investigators added: "[N]o participant withdrew because of tolerability issues. Subjects receiving active agent endorsed a ‘good drug effect’ more than a ‘bad drug effect.’"

They concluded: "In the present experiment, cannabis reduced pain intensity and unpleasantness equally. Thus, as with opioids, cannabis does not rely on a relaxing or tranquilizing effect, but rather reduces both the core component of nociception (nerve pain) and the emotional aspect of the pain experience to an equal degree."

The study is the second clinical trial conducted by CMCR investigators to conclude that inhaled cannabis significantly reduces chronic neuropathy, a condition that is typically unresponsive to both opioids and non-steroidal anti-inflammatory drugs such as ibuprofen.

Commenting on the study’s the findings, NORML Deputy Director Paul Armentano said: "With the results of each published study it becomes increasingly apparent why the US government has tried consistently to stonewall clinical research on the therapeutic effects of inhaled cannabis. Each new trial the Feds approve provides additional evidence undermining the government’s ‘flat Earth’ position that cannabis is without medical value."

For more information, please contact Paul Armentano, NORML Deputy Director, at: paul@norml.org. Full text of the study, "A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain," will appear in the Journal of Pain.

    updated: May 08, 2008

Share This Page Share This Page on digg Share This Page on Reddit Share This Page on del.icio.us Share This Page on Stumble Upon Share This Page on Facebook Share This Page on Twitter Check our RSS Feeds

2009   2008   2007   2006   2005   2004   2003   2002   2001   2000   1999   1998   1997   1996  
Country State/Prov Year Month
Help NORML Fight Unfair Laws
Features
Features
   
NORML
Site MapContact UsSupport NORMLTake ActionLibrary
© 2009 NORML • Privacy StatementSite Terms • Site by Communicopia and Red Aphid
NORML and the NORML Foundation: 1600 K Street NW, Suite 501, Washington DC, 20006-2832
Tel: (202) 483-5500 • Fax: (202) 483-0057 • Email: norml@norml.org